Century Therapeutics Inc (IPSC)vsNovartis AG ADR (NVS)
IPSC
Century Therapeutics Inc
$2.20
0.00%
HEALTHCARE · Cap: $396.78M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 51728% more annual revenue ($56.58B vs $109.16M). NVS leads profitability with a 23.9% profit margin vs -8.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).
IPSC
Avoid27
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IPSC.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6.0% — below average capital efficiency
Revenue declined 100.0%
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IPSC
The strongest argument for IPSC centers on Price/Book.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IPSC
The primary concerns for IPSC are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
IPSC profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
IPSC carries more volatility with a beta of 1.67 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 27/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Century Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Century Therapeutics Inc. (Ticker: IPSC) is an innovative biotechnology firm at the forefront of advancing allogenic cell therapies aimed at transforming cancer treatment. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, the company is committed to developing novel off-the-shelf therapeutic solutions that enhance patient outcomes and broaden accessibility. With a robust pipeline of clinical-stage product candidates and strategic partnerships that bolster its competitive edge, Century Therapeutics is strategically positioned to lead advancements in the burgeoning cell therapy market, offering strong potential for clinical successes and favorable returns for investors.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?